For the new financial year, Cipla expects its topline to see "continued growth trajectory" and the management fell short of ...

The pharmaceutical segment contributed Rs 6,503.63 crore to the quarterly revenue, reflecting an 8.5 per cent growth, while ...

Results: Cipla reported a 30.12% year-on-year increase in Q4FY25 net profit, reaching ₹1,221.84 crore, up from ₹939.04 crore.

Indian pharma giant Cipla released its Q4 FY 25 result, wherein it posted a healthy year-on-year growth of 30% in net profit ...

Profit exceeded Bloomberg estimates by 19.4 per cent, whereas the revenue fell along the expected lens growing 0.28 per cent ...

Cipla celebrates a significant 30% rise in net profit for Q4 FY25, with revenues growing by 9%. The company emphasizes its ...

Managing Director & Global CEO Umang Vohra expressed confidence in the company's ability to expand, driven by a multi-pronged ...

James Sports Group LLC (JSG), one of the nation's premier NIL agencies, today celebrates the completion of JSG's first month ...

Cipla CEO Umang Vohra discusses challenges in pharmaceutical industry, including US tariffs, with uncertain future ahead.

Cipla, the third-largest pharmaceutical company in India by revenue, reported a fourth-quarter profit that exceeded ...

Vohra stated that the directive appears to be primarily aimed at branded pharmaceutical products rather than generic ...

Umang Vohra of Cipla says that the US order to lower drug costs will likely target branded drugs. He believes generic drug ...